GlassScriptPhysician profile
Janet Cupone
NPI 1265898795
$8,206.71
in general payments reported to CMS, 2019-2025
53 companies · $1,811 in 2025
The $1,811 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,805 · 2022: $1,027 · 2023: $1,764 · 2024: $1,799 · 2025: $1,811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,374.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,164.77 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $820.16 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $647.08 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $367.83 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $361.08 | 2021-2025 | Xifaxan |
| Novo Nordisk INC | $355.76 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $330.96 | 2021-2025 | Jardiance, Emgality, Mounjaro |
| Abbott Laboratories | $302.86 | 2021-2025 | Freestyle Libre 2, Assurity, Freestyle Libre 3 |
| Nestle Healthcare Nutrition INC. | $242.64 | 2021 | |
| Astellas Pharma US INC | $222.61 | 2021-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $174.48 | 2021-2025 | Spravato, Xarelto |
| Glaxosmithkline, LLC. | $133.98 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $127.83 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $126.68 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $118.19 | 2023-2024 | Rexulti |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Cupone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.